Literature DB >> 3014126

Botulinum toxin prevents stimulus-induced backfiring produced by neostigmine in the mouse phrenic nerve-diaphragm.

E Aizenman, G G Bierkamper, E F Stanley.   

Abstract

The origin of motor nerve antidromic activity (backfiring) induced by anticholinesterase treatment was examined in the mouse phrenic nerve-hemidiaphragm preparation. Botulinum toxin was used to determine whether backfiring is due to (a) a direct effect of the cholinesterase inhibitor on the nerve terminal, or (b) an indirect effect via the prolongation of the action of acetylcholine. In previously untreated control preparations, neostigmine produced spontaneous and stimulus-induced antidromic activity in the phrenic nerve when rapidly introduced into the diaphragm via its vasculature. This activity could be reversibly blocked by d-tubocurarine and decamethonium, but not by atropine. Neostigmine-induced backfiring did not occur in preparations in which transmitter release was blocked with botulinum toxin. Infusion of a small bolus of a high concentration of acetylcholine following neostigmine treatment resulted in a short-term increase in the incidence of antidromic activity, followed by block, in both controls and botulinum toxin-treated preparations. It is concluded that transmitter release is necessary for the production of backfiring following cholinesterase inhibition since neostigmine alone does not elicit antidromic activity in botulinum toxin-treated preparations at concentrations which are effective in controls. Our results support the hypothesis that the effects of neostigmine on the motoneurone terminal are mediated by the prolonged action of acetylcholine that occurs with inhibition of acetylcholinesterase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014126      PMCID: PMC1192769          DOI: 10.1113/jphysiol.1986.sp016015

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  29 in total

1.  ANTIDROMIC ACTIVITY IN THE RAT PHRENIC NERVE-DIAPHRAGM PREPARATION.

Authors:  M RANDIC; D W STRAUGHAN
Journal:  J Physiol       Date:  1964-09       Impact factor: 5.182

2.  Neuromuscular facilitation and antidromic discharges in motor nerves: their relation to activity in motor nerve terminals.

Authors:  G WERNER
Journal:  J Neurophysiol       Date:  1960-03       Impact factor: 2.714

3.  The effect of magnesium on the activity of motor nerve endings.

Authors:  J DEL CASTILLO; B KATZ
Journal:  J Physiol       Date:  1954-06-28       Impact factor: 5.182

4.  Action of brown widow spider venom and botulinum toxin on the frog neuromuscular junction examined with the freeze-fracture technique.

Authors:  D W Pumplin; T S Reese
Journal:  J Physiol       Date:  1977-12       Impact factor: 5.182

5.  The role of pre-and post-junctional cholinoceptors in the action of neostigmine at the neuromuscular junction.

Authors:  S N Webb; W C Bowman
Journal:  Clin Exp Pharmacol Physiol       Date:  1974 Mar-Apr       Impact factor: 2.557

6.  Subacute denervation: a means of disclosing mammalian motor nerve terminals as critical sites of acetylcholine and facilitatory drug actions.

Authors:  M Okamoto; W F Riker
Journal:  J Pharmacol Exp Ther       Date:  1969-04       Impact factor: 4.030

7.  Botulinum toxin: mechanism of presynaptic blockade.

Authors:  I Kao; D B Drachman; D L Price
Journal:  Science       Date:  1976-09-24       Impact factor: 47.728

Review 8.  Prejunctional and postjunctional cholinoceptors at the neuromuscular junction.

Authors:  W C Bowman
Journal:  Anesth Analg       Date:  1980-12       Impact factor: 5.108

9.  The effect of acetylcholine upon mammalian motor nerve terminals.

Authors:  J I Hubbard; R F Schmidt; T Yokota
Journal:  J Physiol       Date:  1965-12       Impact factor: 5.182

10.  Botulinum toxin blocks quantal but not non-quantal release of ACh at the neuromuscular junction.

Authors:  E F Stanley; D B Drachman
Journal:  Brain Res       Date:  1983-02-14       Impact factor: 3.252

View more
  6 in total

1.  The effects of nerve terminal activity on non-quantal release of acetylcholine at the mouse neuromuscular junction.

Authors:  H Zemková; F Vyskocil; C Edwards
Journal:  J Physiol       Date:  1990-04       Impact factor: 5.182

2.  Prevention of diisopropylphosphorofluoridate-induced myopathy by botulinum toxin type A blockage of quantal release of acetylcholine.

Authors:  D Sket; W D Dettbarn; M E Clinton; K E Misulis; J Sketelj; D Cucek; M Brzin
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

3.  Effects of tetrodotoxin, Ca2+ absence, d-tubocurarine and vesamicol on spontaneous acetylcholine release from rat muscle.

Authors:  V Dolezal; S Tucek
Journal:  J Physiol       Date:  1992-12       Impact factor: 5.182

4.  The origin of the anticholinesterase-induced repetitive activity of the phrenic nerve-diaphragm preparation of the rat in vitro.

Authors:  C B Ferry
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

5.  The nature of the presynaptic effects of (+)-tubocurarine at the mouse neuromuscular junction.

Authors:  C B Ferry; S S Kelly
Journal:  J Physiol       Date:  1988-09       Impact factor: 5.182

6.  A mouse model of Schwartz-Jampel syndrome reveals myelinating Schwann cell dysfunction with persistent axonal depolarization in vitro and distal peripheral nerve hyperexcitability when perlecan is lacking.

Authors:  Marie Bangratz; Nadège Sarrazin; Jérôme Devaux; Désirée Zambroni; Andoni Echaniz-Laguna; Frédérique René; Delphine Boërio; Claire-Sophie Davoine; Bertrand Fontaine; Maria Laura Feltri; Evelyne Benoit; Sophie Nicole
Journal:  Am J Pathol       Date:  2012-03-23       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.